Results of membrane-activated chelator stroke intervention randomized trial of DP-b99 in acute ischemic stroke

Stroke

Volumn 44, Issue 3, 2013, Pages 580-584

  Lees, Kennedy R ^a   Bornstein, Natan ^b   Diener, Hans Christoph ^c   Gorelick, Philip B ^d   Rosenberg, Gilad ^e   Shuaib, Ashfaq ^f  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF ILLINOIS   (United States)

^e D Pharm Ltd   (Israel)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acute treatment; Neuroprotection; Randomized controlled trial

Indexed keywords

ALTEPLASE; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; PLACEBO;

ADVERSE OUTCOME; AGED; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SCORING SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; CHELATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EGTAZIC ACID; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876264634     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000013     Document Type: Article

References (26)

1. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
4. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. J Am Med Assoc. 1999;282:2003-2011.
5. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38:967-973.
6. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet. 2000;355:1949-1954.
7. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, et al. Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke. 2000;31:2543-2551.
8. Tirilazad International Steering Committee. Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke.2000; 31:2257-2265.
9. Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, et al; CLASS-I/H/T Investigators. Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke. 2002;33:122-128.
10. Lees KR; Muir KW; Ford I; Reid JL; Mendelow AD; Sandercock PAG et al. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet. 2004;363:439-445.
11. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
12. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al; SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571.
13. Galasso SL, Dyck RH. The role of zinc in cerebral ischemia. Mol Med. 2007;13:380-387.
14. Barkalifa R, Hershfinkel M, Friedman JE, Kozak A, Sekler I. The lipophilic zinc chelator DP-b99 prevents zinc induced neuronal death. Eur J Pharmacol. 2009;618:15-21.
15. Angel I, Bar A, Horovitz T, Taler G, Krakovsky M, Resnitsky D, et al. Metal ion chelation in neurodegenerative disorders. Drug Dev Res 2002;56:300-9.
16. Striem S, Schatz G, Krakovsky M, Finkelstein E, Kozak A, Angel I, Friedman JE. The effect of DP-b99, a lipophilic divalent transition metal chelator, on Matrix Metalloproteinases-2 and-9 activity in a rat MCAO ischemic model. Neural Plast. 2003;10:234 (abstract).
17. Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke. 2008;39:1774-1778.
18. Rosenberg G, Bornstein N, Diener HC, Gorelick PB, Shuaib A, Lees K; MACSI investigators. The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal phase III study. Int J Stroke. 2011;6:362-367.
19. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-1711.
20. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457-507.
21. Dmitrienko A, Molenbergh G, Chuang-Stein C, Offen W. Analysis of Clinical Trials Using SAS: A Practical Guide. Cary, NC: SAS Institute, Inc; 2005;246-249.
22. Quinn TJ, Dawson J, Lees JS, Chang TP, Walters MR, Lees KR; GAIN and VISTA Investigators. Time spent at home poststroke: "home-time" a meaningful and robust outcome measure for stroke trials. Stroke. 2008;39:231-233.
23. Lees KR, Bath PM, Schellinger PD, Kerr DM, Fulton R, Hacke W, et al; European Stroke Organization Outcomes Working Group. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke. 2012;43:1163-1170.
24. Bath PM, Lees KR, Schellinger PD, Altman H, Bland M, Hogg C, et al; European Stroke Organisation Outcomes Working Group. Statistical analysis of the primary outcome in acute stroke trials. Stroke. 2012;43:1171-1178.
25. Quinn TJ, Lees KR, Hardemark HG, Dawson J, Walters MR. Initial experience of a digital training resource for modified Rankin scale assessment in clinical trials. Stroke. 2007;38:2257-2261.
26. Ali M, Bath P, Brady M, Davis S, Diener HC, Donnan G, et al; VISTA Steering Committees. Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses. Int J Stroke. 2012;7:133-138.